Clarus Wealth Advisors Takes Position in Pfizer (PFE)

Clarus Wealth Advisors purchased a new stake in shares of Pfizer (NYSE:PFE) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,056 shares of the biopharmaceutical company’s stock, valued at approximately $400,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Grimes & Company Inc. grew its stake in shares of Pfizer by 15.8% during the fourth quarter. Grimes & Company Inc. now owns 67,101 shares of the biopharmaceutical company’s stock valued at $2,430,000 after buying an additional 9,143 shares during the last quarter. Essex Investment Management Co. LLC grew its stake in shares of Pfizer by 28.3% during the fourth quarter. Essex Investment Management Co. LLC now owns 24,653 shares of the biopharmaceutical company’s stock valued at $893,000 after buying an additional 5,440 shares during the last quarter. QCI Asset Management Inc. NY grew its stake in shares of Pfizer by 62.7% during the fourth quarter. QCI Asset Management Inc. NY now owns 5,002 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 1,928 shares during the last quarter. Columbia Asset Management grew its stake in shares of Pfizer by 1.6% during the fourth quarter. Columbia Asset Management now owns 101,946 shares of the biopharmaceutical company’s stock valued at $3,692,000 after buying an additional 1,560 shares during the last quarter. Finally, Bank of The Ozarks grew its stake in shares of Pfizer by 24.6% during the fourth quarter. Bank of The Ozarks now owns 69,624 shares of the biopharmaceutical company’s stock valued at $2,522,000 after buying an additional 13,728 shares during the last quarter. Institutional investors and hedge funds own 71.19% of the company’s stock.

How to Become a New Pot Stock Millionaire

Pfizer stock opened at $36.63 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. The company has a market cap of $217,220.05, a price-to-earnings ratio of 13.82, a PEG ratio of 1.83 and a beta of 0.90. Pfizer has a fifty-two week low of $31.67 and a fifty-two week high of $39.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business’s revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.47 EPS. analysts forecast that Pfizer will post 2.95 earnings per share for the current year.

PFE has been the topic of several recent analyst reports. Morningstar set a $38.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. Barclays cut Pfizer from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $41.00 to $38.00 in a research note on Thursday, April 5th. UBS set a $42.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research note on Wednesday, December 27th. Finally, Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research note on Wednesday, January 24th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $39.20.

In other Pfizer news, insider Mikael Dolsten sold 69,699 shares of Pfizer stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $36.59, for a total transaction of $2,550,286.41. Following the sale, the insider now directly owns 120,784 shares of the company’s stock, valued at approximately $4,419,486.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director W Don Cornwell sold 1,758 shares of Pfizer stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total value of $64,676.82. Following the sale, the director now directly owns 1,000 shares in the company, valued at $36,790. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,037 shares of company stock worth $9,064,785. Insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2018/04/21/clarus-wealth-advisors-takes-position-in-pfizer-pfe.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply